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Background: The most important limiting factor in kidney transplantation is the scarcity of donor organs.
Consequently, there is an increased use worldwide of kidneys from older deceased donors. High donor age is a
known risk factor for acute cellular rejection and premature graft failure, and the optimal immunosuppressive
regimen in these circumstances remains to be established.
Methods: We investigated whether induction treatment with an interleukin 2 (IL-2) receptor antagonist improves
graft survival and reduces rejection episodes in recipients of kidneys from deceased donors aged ≥ 60 years. Data
were retrieved for all recipients transplanted at our center from 2004 to 2009 with a kidney from a deceased donor
aged > 60 years. The outcome was compared between recipients treated with (IL-2 plus) or without (IL-2 minus) an
IL-2 receptor antagonist. All recipients received a calcineurin inhibitor, steroids and mycophenolate.
Results: A total of 232 first-transplant recipients were included (IL-2 plus = 149, IL-2 minus = 83). IL-2 minus was
associated with increased risk of early acute rejection (OR 2.42; 95% CI 1.25 to 4.68, P = 0.009) and steroid-resistant
rejection (OR 8.04; 2.77 to 23.25, P< 0.001). IL-2 plus patients had superior two-year estimated uncensored (87%
versus 70%, P = 0.001) and death-censored (95% versus 79%, P< 0.001) graft survival.
Conclusions: Induction treatment with IL-2 receptor antagonist was associated with a reduction in acute rejection
episodes and improved two-year graft survival in patients transplanted with kidneys from older deceased donors.
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Both the incidence and the age of patients with end
stage renal disease (ESRD) starting renal replacement
therapy have increased dramatically during the last 20 to
30 years [1-4]. In selected older patients, kidney trans-
plantation is safe and leads to superior results compared
with continuous dialysis [5].
As the waiting lists grow, there is an ongoing debate
concerning the scarcity of organs and whether it is appro-
priate to use such organs in high-risk recipients, especially
in recipients of advanced age. Increased utilization of
expanded criteria donors (ECD) may be a way to enlarge
the donor pool. An ECD is per definition a deceased* Correspondence: kri-held@online.no
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reproduction in any medium, provided the ordonor who is older than 60 or is 50 to 59 with at least
two of three medical criteria: hypertension, cerebrovas-
cular cause of death or serum creatinine level higher
than 132.6 μmol/L [6]. This definition is based on
organs for which the characteristics were associated
with a relative risk > 1.7 compared with normotensive
donors aged 10 to 39 years for the outcome of overall
transplant loss in a model generated by the Scientific
Registry of Transplant Recipients and published in 2002
[6]. With recent developments in immunosuppression
[7,8], recovery of organs and graft preservation [9], the
overall outcomes for recipients of ECD kidneys may
have improved and those variables found to give in-
creased risk may have been modified. An important
issue in the process of allocation of donor organs is to
match the expected life span of the transplanted organLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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allocation strategy has been used as a tool for matching
the organ with the recipient’s needs and thereby giving
older ESRD patients a possibility of receiving a trans-
plant without displacing younger patients from the
waiting list [10].
The optimal immunosuppressive regimen for kidney
transplantation in an old-to-old setting is not established
[11]. Older recipients have a less active immune response
and consequently develop fewer acute rejection episodes
than younger recipients [12]. Accordingly, some authors
have proposed that older recipients may need less intense
immunosuppression, thus avoiding potentially detrimental
side effects such as serious infections or malignancies
[13]. However, kidneys from older deceased donors may
be more immunogenic [14,15]. This is believed to be
the result of non-specific injuries that induce a pro-
inflammatory milieu which, in turn, may activate immune
responses [16]. In the Eurotransplant Senior Program,
only patients who were transplanted with kidneys from
older donors (> 65 years) had a significantly increased rate
of acute rejection episodes and only about half of these
patients received induction treatment (IL-2 receptor an-
tagonist or T-cell depletion) [10]. The optimal level and
type of immunosuppression in recipients of kidneys from
older donors need to be clarified [5,11].
The aim of our study was to investigate whether there
was any change in outcome after the introduction of
induction treatment with an IL-2 receptor antagonist in
recipients of first kidney transplants of organs from
deceased donors over 60 years of age.
Methods
The study was approved by Oslo University Hospital
and by the regional committee for medical and health
research ethics. All patients included gave their consent
for the use of their clinical data in research. Clinical and
survival data for all patients who received a kidney
transplant from a deceased donor older than 60 years at
Oslo University Hospital between 2004 and the end of
2009 were retrieved from the Norwegian Renal Registry.
The last update of the survival data was performed on 31
December 2012. Patients not treated with a calcineurin in-
hibitor (CNI) as part of the initial regimen were excluded.
Outcome variables including serum creatinine values for
each individual are reported yearly to the registry. Infor-
mation about immunosuppression reflects the initial
regimen used by each patient and that at discharge from
the transplant centre after 10 weeks. Time on dialysis was
defined as the time from start of chronic dialysis to the
time of transplantation. Delayed graft function (DGF) was
defined as the need for dialysis the first week after
transplantation and included patients with primary non-
function. All acute rejection episodes were registered, andthe vast majority were biopsy proven. HLA mismatch was
analyzed as no mismatch versus any mismatch for HLA-A,
-B and -DR, respectively.
In this study, the standard immunosuppressive protocol
for all adult kidney transplant recipients consisted of a
CNI (cyclosporine A (CsA) or tacrolimus), mycophenolate
mofetil (MMF) and corticosteroids. From 2007, induction
treatment with an interleukin 2 receptor (IL-2) antagonist
(basiliximab) was added to this regimen. Initial CsA C2
target levels were 900 to 1100 μg/L, tapered to 800 μg/L
by two months and thereafter CsA C0 levels were 100
to 200 μg/L with gradual reduction towards CsA C0 of
75 to 125 μg/L in the long-term maintenance phase.
From January 2007, tacrolimus was introduced as first
choice CNI for recipients younger than 50 years of age
without known impaired glucose tolerance, and trough
levels were targeted at 3 to 7 μg/L [17]. Recipients older
than 50 years and recipients with pre-transplant impaired
glucose tolerance still received CsA as first choice CNI.
Throughout the study, MMF one gram twice daily in CsA
recipients and 750 mg twice daily in tacrolimus recipients
was used.
Kidneys from deceased donors are accepted at our
center without any upper age limit. The decision to
accept an organ is made based on an overall judgment
of the medical condition of the donor, including hyper-
tension, diabetes, malignancies and age, actual kidney
function (diuresis, creatinine and urea concentrations,
estimated glomerular filtration rate > 60 mL/min) and
results of chemical and microscopic urine analyses. No
patient in the study received an organ from a non-heart-
beating donor.
A two-sided unpaired t-test or Mann–Whitney U-test
was used, as appropriate, to compare groups. Fisher’s
exact test was used to analyze binary data. Uni- and
multivariable logistic regression models were used to
evaluate variables associated with the development of
acute rejection episodes. Survival analyses were performed
using the Kaplan-Meier method and Cox proportional
hazard models with uncensored and death-censored graft
survival as outcomes in the analyses. Available variables
with suspected association with the outcome were first
tested in univariable models. Variables with possible asso-
ciations defined as a P-value ≤ 0.2 in the univariable
model, were then included in the final multivariable
models. Recipient age and gender were implemented in all
models regardless of the results in the univariable model.
There were no missing values in the dataset for any of the
variables included in the multivariable Cox models. Ac-
cordingly, no patient was excluded from the multivariable
models because of missing values. Two patients were
excluded in the acute rejection logistic regression model
because of missing values for cold ischemia time. All
statistical analyses were performed using the statistical
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Results
Between 2004 and the end of 2009, 1,593 kidney trans-
plants were performed at our center. A total of 241
(14%) first-transplant recipients received a kidney from a
deceased donor older than 60 years. Seven recipients did
not receive CNI at transplantation, one received com-
bined heart and kidney transplants and one received two
kidneys. These recipients were excluded, leaving 232 re-
cipients to be included in the final analyses. The major-
ity received CsA (N =206); 164 recipients (71%) were
male. The median age of recipients at time of transplant-
ation was 64.6 years (range 14.9 to 82.8 years). Median
donor age was 67.0 years (60.2 to 89.0 years). OneTable 1 Transplantation characteristics and
immunosuppressive treatment
IL-2 plus IL-2 minus P
(N=149) (N=83)
Characteristics
Recipient gender (male) 105 (71%) 59 (71%) ns
Recipient age (years);
median (range)
64.5 (14.9 to 82.8) 65.8 (32.1 to 80.5) ns
Donor gender (male) 100 (67%) 38 (46%) 0.002
Donor age (years); median
(range)
67.6 (60.2 to 89.0) 65.5 (60.3 to 78.8) 0.03
Time on dialysis (years);
median (range)
1.5 (0.0 to 6.3) 1.4 (0.0 to 5.9) ns
Diabetic nephropathy 14 (9%) 8 (10%) ns
Vascular nephropathy 40 (27%) 32 (38%) ns
PRA positive recipients 10 (7%) 4 (5%) ns
Any HLA-A mismatch 122 (82%) 62 (75%) ns
Any HLA-B mismatch 130 (87%) 78 (94%) ns
Any HLA-DR mismatch 82 (55%) 41 (49%) ns
CMV-positive recipient 125 (84%) 57 (69%) 0.01
CMV-positive donor 121 (82%) 72 (87%) ns
Cold ischemia time
(hours); mean ± SD









CsA 126 (85%) 80 (96%) 0.008
Tacrolimus 23 (15%) 3 (4%) 0.008
PRA, panel-reactive
antibodieshundred and forty-nine recipients were treated with IL-2
antagonist (IL-2 plus) versus 83 recipients without IL-2
antagonist treatment (IL-2 minus). Median follow-up
was 4.4 years (range 0 to 8.9 years). Recipient age and
sex, time on dialysis before transplantation, HLA-
mismatches (−A, -B, -DR), cold ischemia time (CIT) and
DGF did not differ between the groups. The proportion
of cytomegalovirus (CMV)-positive recipients and male
donors, as well as the donor age, was significantly higher
in the IL-2 plus group. Baseline characteristics are
presented in Table 1. At 10 weeks after transplantation,
patients in the IL-2 plus group had significantly lower
CsA C0 concentrations than those in the IL-2 minus
group. Details of immunosuppression at 10 weeks are
presented in Table 2. Seventy-nine patients died during
the follow-up. Causes of death were cardiovascularTable 2 Follow-up variables; immunosuppression,
outcome and cause of graft loss




CsA 99 (67%) 60 (77%) ns
Tacrolimus 31 (21%) 10 (13%) ns
mTOR inhibitor 14 (10%) 9 (12%) ns
CsA dose (mg/day) 250.5 ± 73.5 255.4 ± 87.8 ns
CsA C0 concentration 151.4 ± 56.5 183.3 ± 85.6 0.01
Tacrolimus dose (mg/day) 5.65 ± 2.95 8.70 ± 4.64 ns
Tacrolimus concentration 7.3 ± 2.1 9.2 ± 2.3 ns
Prednisolone dose (mg/day) 12,4 ± 5.6 13.6 ± 5.6 ns
MMF (mg/day) 1678.1 ± 402.9 1750.0 ± 619.9 ns
Outcome
Delayed graft function 53 (36%) 29 (35%) ns
Acute rejection 90 days post
transplant
29 (20%) 34 (41%) 0.001
Acute rejection 180 days post
transplant
38 (26%) 35 (42%) 0.01
Steroid-resistant rejection
(biopsy proven)
5 (3%) 18 (22%) < 0.001
C4D positive biopsy 4 (5%) 4 (3%) ns
Cause of graft loss
Death with functioning graft 32 (22%) 24 (29%) ns
Primary non-function 0 6 (7%) 0.002
Primary vascular thrombosis 3 (2%) 2 (2%) ns
Rejection 5 (3%) 10 (12%) 0.02
Recurrent primary disease 0 1 (1%) ns
Urological complications 1 (1%) 0 ns
De novo glomerulonephritis 1 (1%) 0 ns
Insufficient graft function 0 2 (2%) ns
Not specified 2 (1%) 2 (2%) ns
Figure 2 Death-censored graft survival for patients receiving a
kidney transplant from a deceased donor older than 60 years,
treated with (IL-2 plus, N = 149) or without (IL-2 minus, N = 83)
an IL-2 receptor antagonist.
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nancy in 10 patients, gastro-intestinal diseases in 6
patients and miscellaneous in 10 patients. The causes
of death were balanced between the groups.
In the IL-2 plus group, there were significantly lower
rates of acute rejection episodes after 90 days (P = 0.001)
and 180 days (P = 0.01). In addition, the rate of steroid-
resistant rejection (P< 0.001) was also significantly lower
in the IL-2 plus group. We identified a highly significant
improvement in two-year uncensored and death-censored
graft survival in the IL-2 plus group compared with the
IL-2 minus group (Figures 1 and 2). During the observa-
tion time, 44 grafts (30%) were lost in the IL-2 plus group
versus 47 grafts (57%) in the IL-2 minus group. Rejection
data and causes of graft loss are compared in Table 2.
There were a total of 136 treated acute rejection episodes.
The distribution of transplant indication biopsy Banff
scores are presented in Figure 3. Four patients were diag-
nosed and treated for an acute rejection episode without
biopsy-verification. Two patients had non-representative
biopsies. Most graft losses occurred during the first 90
days post transplantation, and 90-day uncensored graft
survival was 96% and 83% (P = 0.001) in the IL-2 plus and
IL-2 minus groups, respectively. Among those reci-
pients with a functioning graft at one year after trans-
plantation, serum creatinine values did not differ
significantly between the groups; IL-2 plus (N = 121); me-
dian 134 μmol/L (64 to313 μmol/L), IL-2 minus (N = 64);
median 137 μmol/L (71 to 500 μmol/L). Variables associ-
ated with the risk of uncensored and death-censored
graft loss two years after transplantation, are presented
in Tables 3 and 4. Variables associated with increased
risk of an early (first 90 days) acute rejection episode
and development of steroid-resistant rejection leadingFigure 1 Uncensored graft survival for patients receiving a
kidney from a deceased donor older than 60 years, treated
with (IL-2 plus, N=149) or without (IL-2 minus, N=83) an IL-2
receptor antagonist.to anti-thymocyte globulin (ATG) treatment are presented
in Tables 5 and 6. Steroid-resistant rejection was identified
as a possible risk variable for graft loss in the univariable
Cox regression models. However, in the multivariable
models, steroid-resistant rejection was not significantly
associated with the outcome. Because of the association
between lack of IL-2 exposure and development of
steroid-resistant rejection, increased steroid resistant
rejection was considered to be an effect of missing IL-2
exposure and we decided to exclude steroid-resistant
rejection from the initial multivariable Cox regression
models (Model 1). However, we did perform analyses in a
second model (Model 2) and the results of these analyses
are shown in Tables 5 and 6. Patients who experienced
an acute rejection episode during the first 90 days had
significantly impaired kidney function at one year afterFigure 3 Banff scores of transplant biopsies performed on
clinically suspect acute rejection episodes.
Table 3 Two year uncensored graft loss Cox regression analysis
Univariable Multivariable model 1 Multivariable model 2
HR 95% CI P HR 95% CI P HR 95% CI P
Delayed graft function 3.58 1.93 to 6.65 < 0.001 3.12 1.65 to 5.87 < 0.001 3.23 1.82 to 6.09 < 0.001
IL-2 minus 2.63 1.45 to 4.78 0.001 2.28 1.22 to 4.30 0.01 2.02 1.04 to 3.93 0.04
Time on dialysis (per year) 1.28 1.05 to 1.57 0.02 1.27 1.01 to 1.60 0.04 1.27 1.01 to 1.61 ns
Recipient age (per year) 1.03 1.00 to 1.06 0.03 1.02 0.99 to 1.05 ns 1.02 0.99 to 1.05 ns
Any HLA-A mismatch 0.61 0.32 to 1.16 0.1 0.74 0.38 to 1.44 ns 0.68 0.35 to 1.34 ns
Tacrolimus versus CsA 0.34 0.08 to 1.41 0.1 0.44 0.10 to 1.98 ns 0.46 0.10 to 2.11 ns
Recipient gender (male) 1.70 0.82 to 3.54 0.2 1.41 0.66 to 2.99 ns 1.36 0.64 to 2.90 ns
Donor gender (male) 0.72 0.40 to 1.30 0.3 0.80 0.43 to 1.49 ns 0.80 0.43 to 1.50 ns
Steroid-resistant rejection 2.17 1.01 to 4.67 0.05 - - - 1.80 0.78 to 4.15 ns
N = 232; 42 graft loss, no missing variables.
The following variables were tested in the univariable model but not included in the multivariable model: CMV-positive donor, CMV-positive recipient, presence of
HLA antibodies, donor age, any HLA-B or HLA-DR mismatch, cold ischemia time and presence of acute rejection episode 90 or 180 days after transplantation.
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tion episode. Median serum creatinine was 164 μmol/L
(range 88 to 500 μmol/L, N = 53) in the rejection group
versus 125 μmol/L (64 to 313 μmol/L, N = 132) in the
non-rejection group (P< 0.001). There was no signifi-
cant difference in the number of deaths caused by infec-
tion between IL-2 minus (12 patients = 14%) and IL-2
plus (7 patients = 5%).
Discussion
In this single center retrospective analysis of recipients
of organs from deceased donors older than 60 years, the
use of IL-2 antagonist induction was associated with im-
proved short and intermediate (two-year) graft survival.
Outcome was not associated with recipient age or HLA-
matching. We identified a lower early acute rejection
rate and a lower rate of steroid-resistant rejection epi-
sodes when IL-2 antagonists were used. It is noteworthy
that the donor age was higher in the IL-2 plus group
than in the IL-2 minus group. This may indicate that the
negative effect of increased donor age can be reduced by
more aggressive immunosuppressive therapy, such as
induction treatment with an IL-2 antagonist. GreaterTable 4 Two year death-censored Cox regression analysis
Univariable
HR 95% CI P HR
Delayed graft function 5.21 2.17 to 12.48 < 0.001 5.04
IL-2 minus 4.13 1.78 to 9.57 0.001 4.59
Time on dialysis (per year) 1.23 0.94 to 1.63 0.1 1.20
Recipient gender 1.72 0.65 to 4.58 0.3 1.26
Recipient age 1.01 0.98 to 1.05 0.5 1.00
Steroid-resistant rejection 3.65 1.52 to 8.74 0.004
N = 232; 25 graft loss, no missing variables.
The following variables were tested in the univariable model but not included in th
HLA antibodies, donor age, donor gender, any HLA-A, HLA-B or HLA-DR mismatch,
presence of acute rejection episodes 90 or 180 days after transplantation.donor age and time on dialysis prior to transplantation
have previously been shown to negatively affect graft
survival in older recipients [18]. The number of grafts
with primary non-function differed between the groups
(Table 2). This cannot be explained by introduction of
any new preservation methods or surgical techniques.
When the patients with primary non-function were re-
moved from the models, the results were robust in all
models, except in the uncensored graft loss model.
The use of ECD to increase the available donor pool
has been reported to result in impaired but acceptable
outcomes when compared with outcomes using stand-
ard criteria donors [19-21]. Studies describing the use
of IL-2 antagonists in transplantation with ECD are
scarce. Webster et al. for the Cochrane Collaboration [7]
identified 32 studies with a total of 5,854 adult recipients
where IL-2 antagonists were compared with placebo.
However, none of these studies focused on IL-2 antago-
nists and the use of ECD kidneys or kidneys from older
deceased donors. They found that graft loss, including
death with a functioning graft, was reduced by 25% at six
months and one year but not beyond that. As seen in our
study, the incidence of early biopsy-proven acute rejectionMultivariable model 1 Multivariable model 2
95% CI P HR 95% CI P
2.05 to 12.42 < 0.001 5.41 2.20 to 13.34 < 0.001
1.91 to 11.02 0.001 3.81 1.53 to 9.49 0.004
0.89 to 1.62 ns 1.22 0.91 to 1.63 ns
0.46 to 3.43 ns 1.23 0.45 to 3.34 ns
0.97 to 1.03 ns 1.00 0.97 to 1.04 ns
2.52 1.01 to 6.29 0.05
e multivariable model: CMV-positive donor, CMV-positive recipient, presence of
type of calcineurin inhibitor (tacrolimus versus CsA), cold ischemia time and
Table 5 Logistic regression analysis: acute rejection episodes during the first 90 days after transplantation
Univariable Multivariable
OR 95% CI P OR 95% CI P
IL-2 minus 2.87 1.58 to 5.21 0.001 2.42 1.25 to 4.68 0.009
Any HLA-DR mismatch 1.98 1.09 to 3.60 0.03 2.32 1.19 to 4.52 0.01
Cold ischemia time (per hour) 0.90 0.84 to 0.96 0.001 0.90 0.84 to 0.97 0.003
Tacrolimus versus CsA 0.20 0.05 to 0.86 0.03 0.28 0.04 to 1.01 ns
CMV-positive recipient 0.46 0.24 to 0.90 0.02 0.62 0.30 to 1.30 ns
Time on dialysis (per year) 0.84 0.66 to 1.06 0.14 0.82 0.63 to 1.06 ns
Recipient age 1.00 0.98 to 1.02 0.88 0.98 0.95 to 1.01 ns
Recipient gender (male) 1.46 0.75 to 2.84 0.26 1.46 0.70 to 1.01 ns
N=230; 63 rejection episodes, two patients excluded because of missing variables.
The following variables were tested in the univariable model but not included in the multivariable model: CMV-positive donor, presence of HLA antibodies, donor
gender, donor age, delayed graft function, any HLA-A or any HLA-B mismatch.
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IL-2 antagonist induction with ATG induction [7] and
found no difference between these two regimens for graft
loss at any time or for clinically diagnosed acute rejection.
However, they described a 75% increase in malignancy
and a 32% increase in CMV disease among patients who
received ATG compared with IL-2 antagonist induction.
Others have described reduced patient survival after
ATG induction in older (> 60 years) recipients given
doses > 6 mg/kg [22].
At our center, we have historically experienced a
relatively high rate of acute cellular rejection episodes
[5]. Recipients treated with IL-2 receptor antagonist in-
duction had a significantly lower risk of experiencing
an acute cellular rejection. Perhaps even more import-
ant in an elderly population is that this induction
treatment was strongly and significantly associated
with a reduced rate of steroid-resistant rejection.
Treatment of steroid-resistant rejection episodes with
ATG may be associated with several serious complica-
tions [7,23], especially in a group of older patients
who are receiving the majority of their organs from
older donors [22]. We therefore regard this protective
effect as very important because it leads to fewer rejec-
tion episodes and, in particular, fewer steroid-resistant
rejection episodes.Table 6 Logistic regression analysis: ATG treated steroid-resis
Univariable
OR 95% CI
IL-2 minus 7.98 2.84 to 22.41
Any HLA-DR mismatch 2.18 0.86 to 5.52
CMV-positive recipient 0.38 0.15 to 0.94
Recipient age 0.99 0.96 to 1.03
Recipient gender (male) 1.55 0.55 to 4.37
N=232; 23 rejection episodes, no missing variables.
Variables tested in the univariable model but not included in the multivariable mod
type of calcineurin inhibitor (tacrolimus versus CsA), any HLA-A or HLA-B mismatchAs a result of the logistic regression analysis presented
in Table 6, we considered that the apparent effect ob-
served for steroid-resistant rejection was in fact medi-
ated by lack of IL-2 exposure and was therefore a part of
the causal pathway of graft loss. Accordingly, steroid-
resistant rejection did not satisfy the criteria for a poten-
tial confounder [24] and was omitted from the initial
multivariable models. This consideration was supported
by the result of new analyses in which these two vari-
ables were tested separately and thereafter together in
the same model. In these analyses we observed that the
effect estimates for IL-2 receptor antagonist were only
slightly changed from the univariable analysis when
steroid-resistant rejection was added to the model,
whereas the change was considerable for steroid-
resistant rejection (Table 7).
Because of age-matching policies, most patients re-
ceiving kidneys from older deceased donors are them-
selves older. Concerns have been raised regarding the
increased risk of serious infectious complications related
to increased immunosuppressive load [13,25]. In the
present study, we were not able to detect any increased
incidence of fatal infections in the IL-2 plus group. We
therefore regard the use of IL-2 antagonist induction as
safe, even in older recipients. Unfortunately, we have no
data describing the incidence of non-fatal infectioustant cellular rejection
Multivariable
P OR 95% CI P
< 0.001 8.04 2.77 to 23.25 < 0.001
0.1 2.45 0.92 to 6.57 ns
0.04 0.59 0.22 to 1.58 ns
0.59 0.99 0.95 to 1.02 ns
0.40 1.29 0.42 to 3.95 ns
el: CMV- positive donor, presence of HLA antibodies, donor gender, donor age,
, time on dialysis, cold ischemia time and delayed graft function.
Table 7 Uni- and multivariable models for testing the interaction effect of IL-2 minus and steroid-resistant rejection
Univariable Multivariable
HR 95% CI P HR 95% CI P
Uncensored graft loss
IL-2 minus 2.68 1.46 to 4.91 0.001 2.46 1.30 to 4.67 0.006
Steroid-resistant rejection 2.23 1.03 to 4.80 0.04 1.46 0.66 to 3.29 0.36
Death-censored graft loss
IL-2 minus 4.05 1.75 to 9.39 0.001 3.34 1.37 to 8.13 0.008
Steroid-resistant rejection 3.64 1.52 to 8.72 0.004 2.17 0.86 to 5.46 0.10
Heldal et al. Transplantation Research 2013, 2:11 Page 7 of 9
http://www.transplantationresearch.com/content/2/1/11complications during the post transplant period and are
therefore not able to compare the incidence of less
serious infections.
Compared with those at other transplant centers, the
recipients in our study had a relatively short time on
dialysis prior to transplantation and the mean CIT was
generally short. These are both factors that might be
part of the explanation for our outcome. The presence
of DGF was previously described as a risk variable for
graft loss [10,18]. In this study, we identified DGF as an
independent risk variable in both multivariable regres-
sion models of graft loss, but we found no difference in
the frequency of DGF between the groups (36% versus
35%; Table 1). In the context of marginal donors, any
intervention that could preserve the function of the graft
and reduce the incidence of DGF would be of impor-
tance for the outcome. Improved methods for recovery
of organs and graft preservation may therefore further
improve the outcome of kidney transplantation with
ECD [9].
This study has several limitations. First, it is a retro-
spective and observational study. However, this design
does allow us to generate and test a hypothesis by identify-
ing significant associations between several variables and
the outcomes. The potential to make causal inferences is
as a rule considerably less than in a randomized controlled
trial [26,27]. Our database is, however, complete with
respect to all the variables and events included in the
models. Second, the size of our cohort is relatively small
and the patients were allocated to the two treatment
groups based on the standard protocol at the time of
transplantation, not as a result of randomization. This
introduces another bias, namely the possibility that im-
provements in medical or surgical treatment might be re-
sponsible for the results, not the introduction of an IL-2
antagonist. However, apart from the IL-2 antagonist and
the introduction of tacrolimus as the standard CNI for
recipients younger than 50 years (Table 1), the standard
immunosuppressive protocol has remained virtually
unchanged for the whole study period. After the results
of the SYMPHONY study in 2007 [17], however, there is
reason to believe that some reduction in CNI dose has
been introduced, even if the protocol is unchanged. TheCNI doses and trough levels presented in Table 2
support this belief. The number of patients receiving ta-
crolimus (11%) is far too small to make any conclusions
about which CNI should be preferred. Neither the surgi-
cal procedures nor the procedures for graft recovery
and preservation at our center have changed signifi-
cantly during the period of the study. Accordingly, we
consider that the bias related to improved medical or
surgical treatment is minor. As shown in Table 1, except
for the higher median donor age, the higher rate of male
donors and the higher rate of CMV-positive recipients
in the IL-2 plus group, the groups were comparable.
This study is important as it addresses the utilization
of kidneys from older donors. Most studies performed
addressing modern immunosuppression regimens include
younger recipients and do not focus on donor age. There
is a lack of representation of older patients in randomized
controlled trials [28]. The US Food and Drug Administra-
tion continues to encourage us to study the effects of new
and old immunosuppressive regimens in older patients
[29]. In organ transplantation, there is also a need to focus
on donor age.
In this study, we only investigated recipients of kidneys
from deceased donors older than 60 years of age. ECD
kidneys from deceased donors 50 to 59 years of age with
defined medical criteria [6] were not included in the
analysis. Our results are therefore representative for kid-
neys transplanted from older deceased donors and not
automatically applicable to all ECDs. We do however
believe that these older donors are the most important
reserve of organs available for kidney transplantation
today, and so have the largest potential for expanding
the donor pool.
Finally, the relatively short observational period,
which excludes us from making any conclusions about
the long-term prognosis, is also an important limita-
tion. However, previous studies have shown an obvious
linear relationship between short- and long-term graft
survival [12,19,30].
Conclusions
Induction treatment with IL-2 antagonist is associated
with a reduced incidence of acute rejection episodes and
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http://www.transplantationresearch.com/content/2/1/11improved two-year graft survival in patients receiving a
kidney from a deceased donor older than 60 years. Opti-
mizing immunosuppressive regimens is important, and
adding an IL-2 antagonist to treatment of recipients of
kidneys from older deceased donors may be a way to im-
prove the outcomes. As outcomes improve, increased
utilization of kidneys from older deceased donors may
be an important contribution to alleviation of the scarcity
of donor organs for kidney transplantation.
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